Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Opportunity Knocks For Partnerships In Asia

Executive Summary

ApolloBio signs on to take Inovio's HPV immunotherapy into China and Senju and Fosun sign China partnerships – all part of a wave of Chinese companies looking to bring innovative new medicines to the Greater China markets. Meanwhile, GSK signs on with Indian CRO Syngene.

Advertisement

Related Content

GSK Exercises Right To Buy Out Novartis Consumer Healthcare JV For $13bn
GSK Drops Out Of Auction For Pfizer's Consumer Health Unit
Alnylam and Regeneron Plan 50/50 Gene R&D Pact To Find NASH RNAi Drugs
Celgene Further Commits To Neuroscience With Prothena Pact
Shire's Elaprase Follow-On's Future Uncertain After Trial Miss
GSK Woes Raise Big Pharma R&D Question
Redx Rises Out Of Administration With R&D Refocus
Walmsley Shakes Up GSK; Cuts More Than 30 Drug Development Programs
Syngene Gears For Biologics Build Up
Helsinn’s Family-Business Approach Goes Global In Cancer Care

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC100645

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel